We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Bristol-Myers Squibb (BMY - Free Report) closed at $47.63 in the latest trading session, marking a +1.62% move from the prior day. This move outpaced the S&P 500's daily loss of 0.2%. Elsewhere, the Dow lost 0.17%, while the tech-heavy Nasdaq lost 0.38%.
Prior to today's trading, shares of the biopharmaceutical company had gained 2.09% over the past month. This has outpaced the Medical sector's gain of 1.65% and the S&P 500's gain of 0.33% in that time.
BMY will be looking to display strength as it nears its next earnings release, which is expected to be July 25, 2019. The company is expected to report EPS of $1.03, up 1.98% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.98 billion, up 4.82% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.18 per share and revenue of $24.11 billion. These totals would mark changes of +5.03% and +6.88%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for BMY. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. BMY is holding a Zacks Rank of #1 (Strong Buy) right now.
Looking at its valuation, BMY is holding a Forward P/E ratio of 11.22. This valuation marks a discount compared to its industry's average Forward P/E of 14.49.
We can also see that BMY currently has a PEG ratio of 2.19. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 2.09 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 30, which puts it in the top 12% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Bristol-Myers Squibb (BMY - Free Report) closed at $47.63 in the latest trading session, marking a +1.62% move from the prior day. This move outpaced the S&P 500's daily loss of 0.2%. Elsewhere, the Dow lost 0.17%, while the tech-heavy Nasdaq lost 0.38%.
Prior to today's trading, shares of the biopharmaceutical company had gained 2.09% over the past month. This has outpaced the Medical sector's gain of 1.65% and the S&P 500's gain of 0.33% in that time.
BMY will be looking to display strength as it nears its next earnings release, which is expected to be July 25, 2019. The company is expected to report EPS of $1.03, up 1.98% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.98 billion, up 4.82% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.18 per share and revenue of $24.11 billion. These totals would mark changes of +5.03% and +6.88%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for BMY. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. BMY is holding a Zacks Rank of #1 (Strong Buy) right now.
Looking at its valuation, BMY is holding a Forward P/E ratio of 11.22. This valuation marks a discount compared to its industry's average Forward P/E of 14.49.
We can also see that BMY currently has a PEG ratio of 2.19. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 2.09 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 30, which puts it in the top 12% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.